Rubicon Research Ltd
Company Profile
Business description
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company’s diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
Contact
Road No. 33
MedOne House, B-75
Wagle Estate
Thane West
ThaneMH400 604
INDT: +91 2261414000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
1,141
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
stocks
ASX share plunges due to Iran related weakness
stocks
Investors punish this ASX player after acquisition
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,093.40 | 13.60 | -0.15% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,587.26 | 306.28 | -1.18% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,282.79 | 641.32 | -1.13% |
| NZX 50 Index | 12,989.56 | 191.88 | -1.46% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,907.00 | 4.80 | -0.05% |
| SSE Composite Index | 3,979.26 | 6.96 | -0.17% |